Interaction of tumor suppressor p53 with DNA and proteins

Current Pharmaceutical Biotechnology

Volumn 11, Issue 1, 2010, Pages 122-127

  Wang, Jianxiu ^a   Yang, Julei ^a  

^a CENTRAL SOUTH UNIVERSITY   (China)

Author keywords

Cell lysates; Consensus sequence; DNA; Interaction; Metalloprotein; Monoclonal antibodies; p53

Indexed keywords

DOUBLE STRANDED DNA; METALLOTHIONEIN; MONOCLONAL ANTIBODY; MUTANT PROTEIN; PROTEIN; PROTEIN P53; RNA;

CELL LYSATE; CONSENSUS SEQUENCE; CONTROLLED STUDY; PROTEIN DNA BINDING; PROTEIN DNA INTERACTION; PROTEIN DOMAIN; PROTEIN IMMOBILIZATION; PROTEIN PROTEIN INTERACTION; REVIEW; SURFACE PLASMON RESONANCE; WILD TYPE;

BINDING SITES; DNA; DNA-BINDING PROTEINS; MODELS, BIOLOGICAL; PROTEIN BINDING; PROTEIN INTERACTION MAPPING; TUMOR SUPPRESSOR PROTEIN P53;

EID: 77950130203     PISSN: 13892010     EISSN: 18734316     Source Type: Journal    
DOI: 10.2174/138920110790725366     Document Type: Review

References (52)

1. Balint, E.; Vousden, K. H. Activation and activities of the p53 tumor suppressor protein. Br. J. Cancer, 2002, 85, 1813-1823.
2. Evan, G. I.; Vousden, K. H. Proliferation, cell cycle and apoptosis in cancer. Nature, 2001, 411, 342-348.
3. Polyak, K.; Xia, Y.; Zweier, J. L.; Kinzler, K. W.; Vogelstein, B. A model for p53-induced apoptosis. Nature, 1997, 389, 300-305.
4. Cho, Y.; Gorina, S.; Jeffrey, P. D.; Pavletich, N. P. Crystal structure of p53 tumor suppressor-DNA complex: understanding tumorigenic mutations. Science, 1994, 265, 346-355.
5. Unger, T.; Mietz, J. A.; Scheffner, M.; Yee, C. L.; Howley, P. M. Functional domains of wild-type and mutant p53 proteins involved in transcriptional regulation, transdominant inhibition, and transformation suppression. Mol. Cell. Biol., 1993, 13, 5186-5194.
6. Iwabuchi, K.; Li, B.; Bartel, P.; Fields, S. Use of the two-hybrid system to identify the domain of p53 involved in oligomerization. Oncogene, 1993, 8, 1693-1696.
7. Wang, P.; Reed, M.; Wang, Y.; Mayr, G.; Stenger, J. E.; Anderson, M. E.; Schwedes, J. F.; Tegtmeyer, P. p53 domains: structure, oligomerization and transformation. Mol. Cell. Biol., 1994, 14, 5182-5191.
8. Levine, A. J. p53, the cellular gatekeeper for growth and division. Cell, 1997, 88, 323-331.
9. Levine, A. J.; Perry, M. E.; Chang, A.; Silver, A.; Dittmer, D.; Wu, M .; Welsh, D. The 1993 Walter Hubert Lecture: the role of the p53 tumor-suppressor gene in tumorigenesis. Br. J. Cancer, 1994, 69, 409-416.
10. Hollstein, M.; Sidransky, D.; Vogelstein, B.; Harris, C. C. p53 mutations in human cancers. Science, 1991, 253, 49-53.
11. Takahashi, T.; Nau, M. M.; Chiba, I.; Birrer, M. J.; Rosenberg, R. K.; Vinocour, M.; Levitt, M.; Pass, H.; Gazdar, A. F.; Minna, J. D. p53: a frequent target for genetic abnormalities in lung cancer. Science, 1989, 246, 491-494.
12. Harris, C. C. p53: at the crossroads of molecular carcinogenesis and risk assessment. Science, 1993, 262, 1980-1981.
13. Nigro, J. M.; Baker, S. J.; Preisinger, A. C.; Jessup, J. M.; Hostetter, R.; Cleary, K.; Bigner, S. H.; Davidson, N.; Baylin, S. Mutations in the p53 gene occur in diverse human tumor types. Nature, 1989, 342, 705-708.
14. Mclure, K. G.; Lee, P. W. K. How p53 binds DNA as a tetramer. EMBO J., 1998, 17, 3342-3350.
15. Weintraub, H.; Hauschka, S ; Tapscott, S. J. The MCK enhancer contains a p53 responsive element. Proc. Natl. Acad. Sci. USA, 1991, 88, 4570-4571.
16. El-Deiry, W. S.; Kinzler, S. E.; Pietenpol, J. A.; Kinzler, K. W.; Vogelstein, B. Definition of a consensus binding site for p53. Nat. Genet., 1992, 1, 45-49.
17. Funk, W. D.; Pak, D. T.; Karas, R. H.; Wright, W. E.; Shay, J. W. A transcriptionally active DNA-binding site for human p53 protein complexes. Mol. Cell. Biol., 1992, 12, 2866-2871.
18. Zambetti, G. P.; Bargonetti, J.; Walker, K.; Prives, C ; Levine, A. J. Wild-type p53 medicates positive regulation of gene expression through a specific DNA sequence element. Genes Dev., 1992, 6, 1143-1152.
19. Wu, X. W.; Hayle, J. H.; Olson, D.; Levine, A. J. The p53 MDM2 autoregulatory feedback loop. Genes Dev., 1993, 7, 1126-1132.
20. Miyashita, T.; Reed, J. C. Tumor suppressor p53 is a direct transcriptional activator of the human Bax gene. Cell, 1995, 80, 293-299.
21. Wang, Y.; Schwedes, F. J.; Parks, D.; Mann, K.; Tegtmeyer, P. Interaction of p53 with its consensus DNA-binding site. Mol. Cell. Biol., 1995, 15, 2157-2165.
22. Jagelska, E.; Brazda, V.; Pospisilova, S.; Vojtesek, B.; Palecek, E. New ELISA technique for analysis of p53 protein/DNA binding properties. J. Immunol. Methods, 2002, 267, 227-235.
23. Palecek, E.; Vlk, D.; Stankova, V.; Brazda, V.; Vojtesek, B.; Hupp, T. R.; Schaper, A.; Jovin, T. M. Tumor suppressor protein p53 binds preferentially to supercoiled DNA. Oncogene, 1997, 15, 2201-2209.
24. Brazda, V.; Palecek, J.; Posisilova, S.; Vojtesek, B.; Palecek, E. Specific modulation of p53 binding to consensus sequence within supercoiled DNA by monoclonal antibodies. Biochem. Biophys. Res. Commun., 2000, 267, 934-939.
25. Cherny, D. I.; Striker, G.; Subramaniam, V.; Jett, S. D.; Palecek, E.; Jovin, T. M. DNA bending due to specific p53 and p53 core domain-DNA interactions visualized by electron microscopy. J. Mol. Biol., 1999, 294, 1015-1026.
26. Wang, J.; Zhu, X.; Tu, Q.; Guo, Q.; Zarui, C. S.; Momand, J.; Sun, X. Z.; Zhou, F. Capture of p53 by electrodes modified with consensus DNA deplexes and amplified voltammetric detection using ferrocene-capped gold nanoparticle/streptavidin conjugates. Anal. Chem., 2008, 80, 769-774.
27. Mclure, K. G.; Lee, P. W. K. p53 DNA binding can be modulated by factors that alter the conformational equilibrium. EMBO J., 1999, 18, 763-770.
28. Sun, X. Z.; Vinci, C.; Makmura, L.; Han, S.; Tran, D.; Nguyen, J.; Hamann, M.; Grazziani, S.; Sheppard, S.; Gutova, M.; Zhou, F.; Thomas, J.; Momand, J. Formation of disulfide bond in p53 correlates with inhibition of DNA binding and tetramerization. Antioxid. Redox Sign., 2003, 5, 655-665.
29. Hare, J. L.; Lee, E. Mickael electrophilic addition of biotin to sulfhydryl groups. Biochemistry, 1998, 28, 574-580.
30. Wang, J.; Li, J.; Baca, A. J.; Hu, J.; Zhou, F.; Yan, W.; Pang, D. Amplified voltammetric detection of DNA hybridization via oxidation of ferrocene caps on gold nanoparticle/streptavidin conjugates. Anal. Chem., 2003, 75, 3941-3945.
31. Baca, A. J.; Zhou, F.; Wang, J.; Hu, J.; Li, J.; Wang, J.; Chikneyan, Z. S. Attachment of ferrocene-capped gold nanoparticle/streptavidin conjugates onto electrode surfaces covered with biotinylated biomolecules for enhanced voltammetric analysis. Electroanalysis, 2004, 16, 73-80.
32. Tao, N. J.; Boussaad, S.; Huang, W. L.; Arechabaleta, R. A.; D'Agnese, J. High resolution surface plasmon resonance spectroscopy. Rev. Sci. Instrum., 1999, 70, 4656-4660.
33. Economou, E. N. Surface plasmons in thin films. Phys. Rev., 1969, 182, 539-554.
34. Pockrand, I. Surface plasma oscillations at silver surfaces with thin transparent and absorbing coatings. Surf. Sci., 1978, 72, 577-588.
35. Swalen, J. D.; Gordon, J. G.; Philpott, M. R.; Brillante, A.; Pockrand, I.; Santo, R. Plasmon surface polariton dispersion by direct optical observation. Am. J. Phys., 1980, 48, 669-672.
36. Campagnolo, C.; Meyers, K. J.; Ryan, T.; Atkinson, R. C.; Chen, Y.-T.; Scanlan, M. J.; Ritter, G.; Old, L. J.; Batt, C. A. Real-time, label-free monitoring of tumor antigen and serum antibody interactions. J. Biochem. Biophys. Methods, 2004, 61, 283-298.
37. Hochuli, E.; Doebeli, H.; Schacher, A. New metal chelate adsorbent selective for proteins and peptides containing neighboring histidine residues. J. Chromatogr., 1987, 411, 177-184.
38. Bergendahl, V.; Anthony, L. C.; Heyduk, T.; Burgess, R. R. Oncolumn tris(2-carboxyethyl)phosphine reduction and IC5-maleimide labeling during purification of a RpoC fragment on a nickel-nitrilotriacetic acid column. Anal. Biochem., 2002, 307, 368-374.
39. Wang, Y.; Zhu, X.; Wu, M.; Xia, N.; Wang, J.; Zhou, F. Simultaneous and label-free determination of wild-type and mutant p53 at a single surface plasmon resonance chip preimmobilized with consensus DNA and monoclonal antibody. Anal. Chem., 2009, 81, 8441-8446.
40. Margoshes, M.; Vallee, B. L. A cadmium protein from equine kidney cortex. J. Am. Chem. Soc., 1957, 79, 4813-4814.
41. Hamer, D. H. Metallothionein. Annu. Rev. Biochem., 1986, 55, 913-951.
42. Chan, J.; Huang, Z.; Merrifield, M. E.; Salgado, M. T.; Stillman, M. J. Studies of metal binding reactions in metallothioneins by spectroscopic, molecular biology, and molecular modeling techniques. Coord. Chem. Rev., 2002, 233-234, 319-339.
43. Cherian, M. G.; Jayasurya, A.; Bay, B.-H. Metallothioneins in human tumors and potential roles in carcinogenesis. Mutat. Res., 2003, 533, 201-209.
44. Rainwater, R.; Parks, D.; Anderson, M. E.; Tegtmeyer, P.; Mann, K. Role of cysteine residues in regulation of p53 function. Mol. Cell. Biol., 1995, 15, 3892-3903.
45. Meplan, C.; Richard, M.-J.; Hainaut, P. Metalloregulation of the tumor suppressor protein p53: zinc mediates the renaturation of p53 after exposure to metal chelators in vitro and in intact cells. Oncogene, 2000, 19, 5227-5236.
46. Hunziker, P. E. Metal removal from mammalian metallothioneins. Methods Enzymol., 1991, 205, 451-452.
47. Jacob, C.; Maret, W.; Vallee, B. L. Control of zinc transfer between thionein, metallothionein, and zinc proteins. Proc. Natl. Acad. Sci. USA, 1998, 95, 3489-3494.
48. Xia, N.; Liu, L.; Yi, X.; Wang, J. Studies of interaction of tumor suppressor p53 with apo-MT using surface plasmon resonance. Anal. Bioanal. Chem., 2009, 395, 2569-2575.
49. Ostrakhovitch, E. A.; Olsson, P.-E.; Jiang, S.; Cherian, M. G. Interaction of metallothionein with tumor suppressor p53 protein. FEBS Lett., 2006, 580, 1235-1238.
50. Bullock, A. N.; Henckel, J.; DeDecker, B. S.; Johnson, C. M.; Nikolova, P. V.; Proctor, M. R.; Lane, D. P.; Fersht, A. R. Thermodynamic stability of wild-type and mutant p53 core domain. Proc. Natl. Acad. Sci. USA, 1997, 94, 14338-14342.
51. Nichols, N. M.; Matthews, K. S. p53 unfolding detected by CD but not by tryptophan fluorescence. Biochem. Biophys. Res. Commun., 2001, 288, 111-115.
52. Bell, S.; Hansen, S.; Buchner, J. Refolding and structural characterization of the human p53 tumor suppressor protein. Biophys. Chem., 2002, 96, 243-257.